Paul Severson

2.5k total citations
39 papers, 573 citations indexed

About

Paul Severson is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Paul Severson has authored 39 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Hematology. Recurrent topics in Paul Severson's work include Melanoma and MAPK Pathways (9 papers), Epigenetics and DNA Methylation (7 papers) and Protein Degradation and Inhibitors (7 papers). Paul Severson is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), Epigenetics and DNA Methylation (7 papers) and Protein Degradation and Inhibitors (7 papers). Paul Severson collaborates with scholars based in United States, France and Czechia. Paul Severson's co-authors include Bernard W. Futscher, Lukáš Vrba, Sabine U. Vorrink, Frederick E. Domann, Mikhail V. Kulak, Brian L. West, Walter T. Klimecki, Michael P. Waalkes, Erik J. Tokar and Fei Zhao and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Paul Severson

37 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Severson United States 12 304 123 115 91 61 39 573
Zuanel Diaz Canada 13 283 0.9× 135 1.1× 31 0.3× 124 1.4× 44 0.7× 21 605
Daniel P. Gaile United States 15 369 1.2× 130 1.1× 45 0.4× 159 1.7× 45 0.7× 41 720
Huei‐Sheng Huang Taiwan 17 430 1.4× 82 0.7× 85 0.7× 114 1.3× 46 0.8× 27 609
Xiaonian Zhu China 15 309 1.0× 159 1.3× 86 0.7× 142 1.6× 19 0.3× 65 633
Joseph F. Pulliam United States 12 306 1.0× 86 0.7× 22 0.2× 75 0.8× 24 0.4× 17 636
Robert R. Roussel United States 7 317 1.0× 56 0.5× 66 0.6× 76 0.8× 110 1.8× 11 520
Arindam Dhar United States 12 595 2.0× 225 1.8× 117 1.0× 135 1.5× 10 0.2× 35 903
Ali Zekri Iran 17 353 1.2× 138 1.1× 33 0.3× 114 1.3× 13 0.2× 38 583
Emily A. Stevens United States 10 150 0.5× 50 0.4× 115 1.0× 58 0.6× 10 0.2× 15 546
Xi Huang China 17 340 1.1× 199 1.6× 139 1.2× 107 1.2× 4 0.1× 45 711

Countries citing papers authored by Paul Severson

Since Specialization
Citations

This map shows the geographic impact of Paul Severson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Severson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Severson more than expected).

Fields of papers citing papers by Paul Severson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Severson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Severson. The network helps show where Paul Severson may publish in the future.

Co-authorship network of co-authors of Paul Severson

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Severson. A scholar is included among the top collaborators of Paul Severson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Severson. Paul Severson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Garmezy, Benjamin, Mitesh J. Borad, Cesar A. Perez, et al.. (2024). A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer Research Communications. 4(4). 1165–1173. 9 indexed citations
3.
Cassier, Philippe A., Janice M. Mehnert, Richard D. Kim, et al.. (2024). 613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors. Annals of Oncology. 35. S491–S492. 2 indexed citations
4.
5.
6.
Severson, Paul, et al.. (2023). ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.. Journal of Clinical Oncology. 41(16_suppl). 3049–3049. 1 indexed citations
7.
Sathyasaikumar, Korrapati V., Verónica Pérez de la Cruz, Benjamín Pineda, et al.. (2022). Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma. Antioxidants. 11(2). 315–315. 19 indexed citations
8.
Franovic, Aleksandra, Sean Uryu, Qibiao Wu, et al.. (2022). Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.. Journal of Clinical Oncology. 40(4_suppl). 461–461. 7 indexed citations
9.
Franovic, Aleksandra, Nichol Miller, Paul Severson, et al.. (2021). The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.. Journal of Clinical Oncology. 39(15_suppl). 3116–3116. 9 indexed citations
10.
Lee, Lauren, Yoshiyuki Hizukuri, Paul Severson, et al.. (2021). A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 106(4). 1022–1033. 10 indexed citations
11.
Gouda, Mohamed A., Eric J. Sherman, Glynn Weldon Gilcrease, et al.. (2020). 529MO Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer. Annals of Oncology. 31. S465–S465. 2 indexed citations
12.
13.
Severson, Paul, Lukáš Vrba, Martha R. Stampfer, & Bernard W. Futscher. (2014). Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 775-776. 48–54. 28 indexed citations
14.
Vorrink, Sabine U., Paul Severson, Mikhail V. Kulak, Bernard W. Futscher, & Frederick E. Domann. (2013). Hypoxia perturbs aryl hydrocarbon receptor signaling and CYP1A1 expression induced by PCB 126 in human skin and liver-derived cell lines. Toxicology and Applied Pharmacology. 274(3). 408–416. 64 indexed citations
15.
Severson, Paul, Erik J. Tokar, Lukáš Vrba, Michael P. Waalkes, & Bernard W. Futscher. (2013). Coordinate H3K9 and DNA methylation silencing of ZNFs in toxicant-induced malignant transformation. Epigenetics. 8(10). 1080–1088. 34 indexed citations
16.
Zhao, Fei, et al.. (2013). Arsenic exposure induces the Warburg effect in cultured human cells. Toxicology and Applied Pharmacology. 271(1). 72–77. 56 indexed citations
17.
Clarke, John, Petr Novák, April D. Lake, et al.. (2013). Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences. 59(2). 365–374. 33 indexed citations
18.
Severson, Paul, et al.. (2012). Agglomerates of aberrant DNA methylation are associated with toxicant-induced malignant transformation. Epigenetics. 7(11). 1238–1248. 22 indexed citations
19.
20.
Grand, Cory L., et al.. (2007). MP470 suppresses repair of double-strand breaks following treatment with DNA-damaging agents.. Molecular Cancer Therapeutics. 6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zuanel Diaz Breakdown of academic impact, for papers by Daniel P. Gaile Breakdown of academic impact, for papers by Huei‐Sheng Huang Breakdown of academic impact, for papers by Xiaonian Zhu Breakdown of academic impact, for papers by Joseph F. Pulliam Breakdown of academic impact, for papers by Robert R. Roussel Breakdown of academic impact, for papers by Arindam Dhar Breakdown of academic impact, for papers by Ali Zekri Breakdown of academic impact, for papers by Emily A. Stevens Breakdown of academic impact, for papers by Xi Huang
Rankless by CCL
2026